WEKO3
アイテム
{"_buckets": {"deposit": "c3f0ba2d-3a2b-42f8-a387-89bf264cbb44"}, "_deposit": {"id": "21634", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "21634"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00021634", "sets": ["456", "1189"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "New Drugs for DIC"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1991-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "108", "bibliographicPageStart": "103", "bibliographicVolumeNumber": "105", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Heparin has long been used for disseminated intravascular coagulation (DIC), but recently some new drugs have become available for DIC. The concentrate of Antithrombin III, which is a physiological protease inhibitor, is used in combination with heparin. Low molecular weight heparin (LMWH) with molecular weight of about 4000~6000 has more anti-X_a activity than anti-IIa activity. For this reason, LMWH has an anticoagulant activity with a low bleeding risk. Synthetic protease inhibitors (eg. FUTHAN) directly inhibit several protease activities in the absence of antithrombin III. Activated protein C inactivates V_a and VIII_a with protein S as a cofactor, and inhibits plasminogen activator inhibitor. Its concentrate may be effective for patients with DIC especially caused by endotoxicemia. DIC is heterogeneous in coagulation-fibrinolysis balance and is associated with various diseases, so we must choose suitable drugs for individual patients.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "132009", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Tatewaki, Wataru"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "帯刀, 亘"}], "nameIdentifiers": [{"nameIdentifier": "132008", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-16"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "105(2)_103-108.pdf", "filesize": [{"value": "1.3 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1300000.0, "url": {"label": "105(2)_103-108.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/21634/files/105(2)_103-108.pdf"}, "version_id": "89d1954a-09b9-46fd-be64-69866c11483e"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "low molecular weight heparin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "synthetic protease inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "activated protein C", "subitem_subject_scheme": "Other"}, {"subitem_subject": "低分子ヘパリン", "subitem_subject_scheme": "Other"}, {"subitem_subject": "合成蛋白分解酵素阻害剤", "subitem_subject_scheme": "Other"}, {"subitem_subject": "活性化プロテインC", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会)"}, {"subitem_title": "5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "1189"], "permalink_uri": "http://hdl.handle.net/10191/38609", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-02-22"}, "publish_date": "2016-02-22", "publish_status": "0", "recid": "21634", "relation": {}, "relation_version_is_last": true, "title": ["5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会)"], "weko_shared_id": null}
5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会)
http://hdl.handle.net/10191/38609
http://hdl.handle.net/10191/386093de8fd66-259c-4018-a4ad-5e5ed50b6d6c
名前 / ファイル | ライセンス | アクション |
---|---|---|
105(2)_103-108.pdf (1.3 MB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-02-22 | |||||
タイトル | ||||||
タイトル | 5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会) | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | 5) DICの新しい治療薬F(シンポジウム DIC-診断・治療の最近の動向, 第457回新潟医学会) | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | low molecular weight heparin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | synthetic protease inhibitor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | activated protein C | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 低分子ヘパリン | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 合成蛋白分解酵素阻害剤 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 活性化プロテインC | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | New Drugs for DIC | |||||
著者 |
帯刀, 亘
× 帯刀, 亘 |
|||||
著者別名 | ||||||
識別子 | 132009 | |||||
識別子Scheme | WEKO | |||||
姓名 | Tatewaki, Wataru | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Heparin has long been used for disseminated intravascular coagulation (DIC), but recently some new drugs have become available for DIC. The concentrate of Antithrombin III, which is a physiological protease inhibitor, is used in combination with heparin. Low molecular weight heparin (LMWH) with molecular weight of about 4000~6000 has more anti-X_a activity than anti-IIa activity. For this reason, LMWH has an anticoagulant activity with a low bleeding risk. Synthetic protease inhibitors (eg. FUTHAN) directly inhibit several protease activities in the absence of antithrombin III. Activated protein C inactivates V_a and VIII_a with protein S as a cofactor, and inhibits plasminogen activator inhibitor. Its concentrate may be effective for patients with DIC especially caused by endotoxicemia. DIC is heterogeneous in coagulation-fibrinolysis balance and is associated with various diseases, so we must choose suitable drugs for individual patients. | |||||
書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 105, 号 2, p. 103-108, 発行日 1991-02 |
|||||
出版者 | ||||||
出版者 | 新潟医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00290440 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00182415 | |||||
著者版フラグ | ||||||
値 | publisher |